SCHEMBL9922654

SCHEMBL9922654

O=C(Nc1ccc(-c2cc(=O)[nH]c3ccccc3c2=O)c(Cl)c1)NS(=O)(=O)c1ccc(Cl)s1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY12 Q9H244 2/20 0.44
ALDH1A1 P00352 5/20 0.41
MAPK1 P28482 1/20 0.41
KMT2A Q03164 7/20 0.40
FBP1 P09467 1/20 0.40
MEN1 O00255 5/20 0.38
MAPT P10636 5/20 0.38
LMNA P02545 4/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
MAOB P27338 1/20 0.38
HTT P42858 3/20 0.38
RECQL P46063 2/20 0.38
MAOA P21397 1/20 0.37
KDM4E B2RXH2 2/20 0.37
GAA P10253 1/20 0.35
POLB P06746 1/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA9 Q16790 1/20 0.35
STING1 Q86WV6 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9922563 0.91 P2RY12 (0.49) P2RY12ALDH1A1MAPK1KMT2AFBP1
SCHEMBL9923254 0.90 P2RY12 (0.49) P2RY12ALDH1A1MAPK1KMT2AFBP1
SCHEMBL12161697 0.89 MAOB (0.46) P2RY12KMT2AFBP1MEN1MAPT
SCHEMBL9922897 0.89 P2RY12 (0.47) P2RY12ALDH1A1MAPK1KMT2AFBP1
SCHEMBL9922219 0.85 P2RY12 (0.45) P2RY12ALDH1A1MAPK1KMT2AFBP1
SCHEMBL9922639 0.84 P2RY12 (0.42) P2RY12ALDH1A1KMT2AFBP1MEN1
SCHEMBL14113588 0.84 P2RY12 (0.49) P2RY12ALDH1A1KMT2AFBP1MEN1
SCHEMBL9922624 0.83 MAOB (0.42) P2RY12ALDH1A1KMT2AFBP1MEN1
SCHEMBL12177512 0.82 P2RY12 (0.42) P2RY12ALDH1A1MAPK1KMT2AMEN1
SCHEMBL12161718 0.81 P2RY12 (0.54) P2RY12ALDH1A1KMT2AFBP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8524721-B2 Platelet ADP receptor inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2013-09-03 US disclosed
US-20120149688-A1 PLATELET ADP RECEPTOR INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-06-14 US disclosed
US-8067428-B2 Platelet ADP receptor inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2011-11-29 US disclosed
US-8067428-B2 Platelet ADP receptor inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2011-11-29 US disclosed
US-20100234350-A1 PLATELET ADP RECEPTOR INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2010-09-16 US disclosed
US-20100234350-A1 PLATELET ADP RECEPTOR INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2010-09-16 US disclosed
US-20080194597-A1 Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis PORTOLA PHARMACEUTICALS, INC. (US) 2008-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234350-A1 PLATELET ADP RECEPTOR INHIBITORS TBXA2R, GP6, P2RY6 P2RY12 19/4885ALDH1A1 1369/4885MAPK1 1846/4885
US-20080194597-A1 Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis PIGS, GP6, ASGR1 P2RY12 89/4885ALDH1A1 1520/4885MAPK1 2015/4885
US-20120149688-A1 PLATELET ADP RECEPTOR INHIBITORS TBXA2R, GP6, P2RY6 P2RY12 18/4885ALDH1A1 1379/4885MAPK1 1820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.